Unity extends gains on data for lead asset in diabetic macular edema

Aug. 15, 2022 6:51 AM ETUnity Biotechnology, Inc. (UBX)REGNBy: Dulan Lokuwithana, SA News Editor2 Comments

Success business chart with green arrow up and USA dollars background. Profit and money. Financial and business graph. Stock market growth 3d illustration.

JuSun/iStock via Getty Images

After a 54% rise on Friday, the shares of clinical-stage biotech Unity Biotechnology (NASDAQ:UBX) continue to trade higher on rising volumes in the pre-market as Wall Street reacts to the company’s Phase 2 data for lead candidate UBX1325 in diabetic macular edema.

Compared to the 65-day volume of ~1.8M, about 3.8M Unity (UBX) shares have changed hands so far on Monday, adding ~17% to the company valuation.

Disclosing the 12- and 18-week data from the BEHOLD study, Unity (UBX) said that a single injection of UBX1325 led to better therapeutic effects compared to the sham control in a patient population, who were under regular anti-VEGF therapy, the current standard of care for DME.

“The drug is exerting a therapeutic effect in a population not expected to meaningfully improve on continued anti-VEGF,” Citi analyst Yigal Nochomovitz wrote in reaction with a Buy rating on Unity (UBX).

The analyst raises the price target on the stock to $8 from $5, citing early proof of proof-of-concept and a higher probability of success for the drug in treating the condition.

Sales of Regeneron’s (REGN) anti-VEGF therapy EYLEA rose ~17% YoY to $5.8B in 2021.

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.